Equillium presents clinical data from equalise phase 1b study in lupus patients at the american society of nephrology annual meeting

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim data from the type a portion of the phase 1b equalise study that showed promising clinical activity in patients with systemic lupus erythematosus (sle), and pharmacokinetic and pharmacodynamic data supporting the anti-cd6 mechanism of itolizumab. the data were pres
EQ Ratings Summary
EQ Quant Ranking